- Home
- MTA vs FULC Comparison
MTA vs FULC Comparison
Compare MTA & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MTA | FULC |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 766.4M | 687.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MTA | FULC |
|---|---|---|
| Price | $8.80 | $10.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 8 |
| Target Price | $9.00 | ★ $16.38 |
| AVG Volume (30 Days) | 595.5K | ★ 843.3K |
| Earning Date | 02-17-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,546,000.00 | N/A |
| Revenue This Year | $127.20 | N/A |
| Revenue Next Year | $75.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 108.91 | ★ 2752.05 |
| 52 Week Low | $2.53 | $2.32 |
| 52 Week High | $8.96 | $15.74 |
Technical Indicators
Market Signals| Indicator | MTA | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 69.29 | 50.47 |
| Support Level | $8.05 | $9.78 |
| Resistance Level | $8.96 | $11.28 |
| Average True Range (ATR) | 0.37 | 0.73 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 84.95 | 78.54 |
Price Performance
Historical ComparisonAbout MTA Metalla Royalty & Streaming Ltd.
Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.